Cerebrolysin is a physician-administered medicine in the countries where it is registered and is not FDA-approved in the US. This page summarizes published safety data; it does not replace clinical evaluation.
Overview
In most randomized trials, Cerebrolysin's side-effect profile looked unremarkable — the pivotal CARS stroke trial called it "safe and well tolerated" with under 5% discontinuation, and a 2025 meta-analysis of 14 trials found serious adverse events and mortality comparable to placebo. Against that stands one important dissent: the 2023 Cochrane review found a roughly doubled rate of non-fatal serious adverse events with moderate certainty. Both findings come from real data, and a fair safety summary carries both.
Tolerability in the trials
- In CARS (205 patients, 30 mL/day IV for 21 days after stroke), Cerebrolysin was described as safe and well tolerated, with premature discontinuation under 5% and a safety profile comparable to placebo (Stroke 2016).
- Across 14 RCTs and 2,884 patients, serious adverse events were no more frequent than placebo (risk ratio 1.08), mortality was comparable, and hemorrhagic transformation was actually lower in treated patients (Cureus 2025).
- The pooled CARS analysis likewise reported safety "comparable to placebo" with a favorable benefit/risk assessment (Neurological Sciences 2017).
The Cochrane serious-adverse-event signal
The 2023 Cochrane review of seven trials (1,773 participants) is the counterweight: it found more people with non-fatal serious adverse events on Cerebrolysin (risk ratio 2.39), a finding rated moderate-certainty, and the signal was stronger in trials using a 30 mL/10-day schedule (Cochrane 2023). All-cause death did not differ. Why Cochrane sees a signal other meta-analyses do not comes down to which trials are included and how events are counted — but a moderate-certainty harm finding from the field's most conservative reviewer is not something an honest safety page can wave away.
Commonly described reactions
Day-to-day, the reactions described in clinical use are mostly mild and infusion-related: sensations of heat or flushing (especially with rapid infusion), dizziness, headache, agitation, and transient nausea — the standard reason it is given as a slow drip rather than a push. Product information in registered markets also lists cautions around epilepsy and severe renal impairment, and, as with any biological product, allergic and hypersensitivity reactions are possible. These are clinician-managed issues; the product is designed for supervised parenteral administration, and decades of registered-market use in Europe and Asia have not produced a distinctive pharmacovigilance scandal — while also never generating the systematic post-marketing safety data an FDA approval would have required.
Risks specific to an animal-derived product
Cerebrolysin is not a defined molecule but a processed extract of pig brain — a fact with two safety consequences. First, its composition depends entirely on manufacturing controls; the regulated product is made under pharmaceutical standards, and that assurance does not transfer to gray-market ampoules of uncertain origin or storage. Second, hypersensitivity to animal-derived proteins is an inherent category of risk that a synthetic peptide would not carry. Combined with the parenteral route, this is a product whose safety story assumes a medical setting — the opposite of the self-injection context in which research vendors present it. See the dosing-education page for how it is actually administered where approved.